Cost-Effectiveness of Early Alzheimer’s Disease Detection Screening
Author Information
Author(s): Jung Yeongin, Wu Kaili, Alnufeay Mashael, Jin Xiaotong, Ballreich Jeromie, Drabo Emmanuel
Primary Institution: Johns Hopkins University
Hypothesis
Is the blood biomarker testing for early-stage Alzheimer's Disease more cost-effective than a sequential approach with Aβ-PET scan confirmation?
Conclusion
Blood biomarker testing alone is more cost-effective than using a sequential approach with Aβ-PET scan for early Alzheimer's detection.
Supporting Evidence
- Strategy 1 produced 891 incremental QALYs at an additional cost of $49.2 million.
- The incremental cost-effectiveness ratio was $55,194/QALY gained.
- The findings were robust to uncertainties in model input parameters.
Takeaway
This study found that testing blood for Alzheimer's signs is cheaper and better than doing a second test with a brain scan.
Methodology
A hybrid model combining a decision tree and a Markov model was used to simulate screening decisions and outcomes over 35 years.
Participant Demographics
Older adults aged 65 and above with early-stage brain abnormalities.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website